Research funding calls

Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)

This funding opportunity supports well-planned clinical trials across the cancer prevention and control spectrum, aiming to improve interception, screening, early detection, healthcare delivery, and survivorship outcomes. It funds preparatory activities and pilot feasibility studies to address information gaps in study population, accrual, and operational risks prior to a full-scale clinical trial. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 25 Feb 2027, 25 Jun 2027, 25 Oct 2027 · Resubmissions: next 25 Oct 2026 · Call expires 26 Oct 2027

Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)

This funding opportunity solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies addressing important biomedical problems. The goal is to establish robust, well-characterized solutions fulfilling unmet needs within five to ten years. Eligible applicant organizations include higher education institutions, non-profits, for-profit organizations, and foreign entities.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 27 May 2027 · Resubmissions: next 27 Jan 2027 · Call expires 8 Sep 2027

Translational Neural Devices (R61/R33 - Clinical Trial Optional)

This National Institutes of Health funding opportunity encourages researchers to pursue translational activities and small clinical studies to advance the development of low-risk therapeutic and diagnostic devices for disorders affecting the nervous or neuromuscular systems. Funded activities include clinical prototype implementation, non-clinical safety testing, design verification, and subsequent small clinical studies. Eligible applicants include domestic and foreign higher education institutions, nonprofits, for-profit organizations, and governments.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Resubmissions: next 28 Jan 2027

Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)

This funding opportunity supports translational activities and clinical studies to accelerate the development of medical devices for disorders within the missions of participating NIH institutes and centers. Funding covers prototype implementation, non-clinical testing, design verification, and clinical studies. Eligible applicants include higher education institutions, non-profits, for-profit organizations, and foreign organizations.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 28 May 2027, 28 Sep 2027, 28 Jan 2028 · Resubmissions: next 28 Jan 2027 · Call expires 29 Jan 2028

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies

This funding opportunity promotes research studies addressing chronic or delayed adverse sequelae resulting from cancer therapies. It supports basic, translational, and clinical research projects to identify mechanisms of therapy-induced adverse sequelae, clinically characterize them, and translate findings into preventive or therapeutic approaches. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations. Projects can include clinical trials.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 5 Jun 2027, 5 Oct 2027 · Resubmissions: next 5 Nov 2026 · Call expires 8 Jan 2028

Laboratories to Optimize Digital Health

This funding opportunity seeks innovative research projects to test and optimize strategies for digital mental health interventions. It supports the development of digital health test beds utilizing established platforms to refine evidence-based interventions and conduct rigorous clinical trials. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations, aiming to improve mental health care reach, efficiency, and clinical effectiveness.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 5 Jun 2027, 5 Oct 2027 · Resubmissions: next 5 Nov 2026 · Call expires 8 Jan 2028

Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)

This funding opportunity seeks research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. The call supports clinical trials designed to establish effectiveness and test mechanisms of action, mediators, and moderators of post-acute phase interventions. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, governments, and non-domestic foreign organizations.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 5 Jun 2027, 5 Oct 2027 · Resubmissions: next 5 Nov 2026 · Call expires 8 Jan 2028

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

This funding opportunity encourages research applications in cancer control and population sciences. It aims to support novel scientific ideas advancing statistical and analytic methods, epidemiology, cancer survivorship, behavioral interventions, healthcare delivery, digital health, and implementation science. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, governments, and foreign organizations. Clinical trials are optional. Awards are limited to $250,000 in direct costs per year with a maximum project period of five years.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 5 Jun 2027, 5 Oct 2027 · Resubmissions: next 5 Nov 2026 · Call expires 8 Jan 2028

Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

This funding opportunity supports research to identify, develop, and test strategies for overcoming barriers to the adoption, integration, sustainability, and scale-up of evidence-based interventions, practices, and policies in health. It aims to bridge the gap between research, practice, and policy by funding rigorous studies, including clinical trials where appropriate, conducted by higher education institutions, nonprofits, governments, and foreign organizations.

Eligible countries: Any country (non-US organisations eligible)

Later deadlines: 5 Jun 2027, 5 Oct 2027 · Resubmissions: next 5 Feb 2027 · Call expires 8 Jan 2028

NCMRR Early Career Research Award (R03 Clinical Trial Optional)

The NCMRR Early Career Research Award supports rehabilitation scientists in establishing independent research careers by funding basic or clinical research projects. The aim is to collect preliminary data for a subsequent R01 application. Eligible applicant organizations include higher education institutions, nonprofits, for-profit organizations, governments, and foreign organizations. Early-stage investigators who are no more than 8 years past their terminal degree may apply as lead investigators.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Must be an independent investigator, no more than 8 years beyond the date their terminal academic degree was awarded. Not a postdoctoral fellow at submission.

Later deadlines: 16 Jun 2027, 16 Oct 2027 · Resubmissions: next 16 Nov 2026 · Call expires 8 Jan 2028

NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)

This funding opportunity supports researchers in planning large-scale clinical vision research projects, including randomized clinical trials and epidemiological studies. It funds the development of study protocols, manuals of procedures, and preliminary studies to assess recruitment potential. Funds cannot be used to test therapeutic interventions. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations. The goal is to ensure rigorous preparation for future clinical studies.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 16 Jun 2027, 16 Oct 2027 · Resubmissions: next 16 Feb 2027 · Call expires 8 Jan 2028

NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)

The National Institutes of Health funding opportunity supports exploratory and developmental research projects during their early and conceptual stages to drive biomedical, behavioral, or clinical breakthroughs. Funded activities include high-risk, innovative studies, novel techniques, and methodologies, and applicants are strictly required to propose at least one clinical trial. Eligible applicant organizations include higher education institutions, non-profits, for-profit organizations, governments, and non-domestic foreign entities.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 16 Jun 2027, 16 Oct 2027 · Resubmissions: next 16 Feb 2027 · Call expires 8 Jan 2028

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)

This funding opportunity encourages exploratory and developmental bioengineering research grant applications to demonstrate feasibility and utility of new capabilities or improvements in biomedical, pre-clinical, or clinical research and clinical care. The initiative supports research aiming to identify cancer risks, causes, and prevention interventions. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, governments, and foreign organizations. The maximum project period is two years with direct costs not exceeding $275,000.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 16 Jun 2027, 16 Oct 2027 · Resubmissions: next 16 Nov 2026 · Call expires 8 Jan 2028

Exploratory/Developmental Bioengineering Research Grants (EBRG)

This National Institutes of Health funding opportunity encourages exploratory and developmental bioengineering research grant applications to demonstrate the feasibility and potential utility of new capabilities or improvements in biomedical, pre-clinical, or clinical research and care delivery. Funded activities include developing novel tools, technologies, or methods without clinical trials. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 16 Jun 2027, 16 Oct 2027 · Resubmissions: next 16 Nov 2026 · Call expires 8 Jan 2028

Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)

This funding opportunity supports exploratory and developmental studies (R21 mechanism) that identify, develop, or test strategies to improve the adoption, scale-up, integration, and sustainability of evidence-based health interventions, policies, and practices. It also encourages research on de-implementing ineffective practices and advancing research methods. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and foreign organizations globally.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 16 Jun 2027, 16 Oct 2027 · Resubmissions: next 16 Feb 2027 · Call expires 8 Jan 2028

Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)

This funding opportunity from the National Institutes of Health supports small research grants (R03) to identify, develop, or test strategies for overcoming barriers to the adoption, integration, sustainability, and scale-up of evidence-based health interventions and policies. Studies advancing dissemination and implementation research methods, measures, or de-implementation of ineffective practices are encouraged. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations. Clinical trials are not allowed.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 16 Jun 2027, 16 Oct 2027 · Resubmissions: next 16 Feb 2027 · Call expires 8 Jan 2028

Confirmatory Efficacy Clinical Trials of Non-Pharmacological and Pharmacological Interventions for Mental Disorders

This funding opportunity supports confirmatory efficacy testing of non-pharmacological and, under certain conditions, pharmacological preventive and therapeutic interventions for mental disorders in adults and children. Projects must employ an experimental therapeutics approach to examine mechanisms of action, target engagement, and clinical outcomes. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the PD/PI is invited to work with their organization

Later deadlines: 15 Jun 2027, 15 Oct 2027 · Resubmissions: next 17 Feb 2027 · Call expires 16 Oct 2027

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders

This funding opportunity supports early-stage clinical trial applications evaluating novel pharmacologic or neuromodulatory device-based interventions for mental disorders. The aim is to test target engagement and mechanism of action alongside clinical or functional outcomes in pediatric, adult, and geriatric populations. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign entities.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 15 Jun 2027, 15 Oct 2027 · Resubmissions: next 17 Feb 2027 · Call expires 16 Oct 2027

Full-Scale Hybrid Effectiveness-Implementation Trials for Mental Health Interventions

This funding opportunity supports well-powered clinical trials to evaluate the effectiveness and implementation of optimized mental health prevention and treatment interventions in real-world settings. Projects must examine implementation challenges, clinical impact, and at least one mechanism of action. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, local and state governments, tribal governments, and foreign organizations.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 15 Jun 2027, 15 Oct 2027 · Resubmissions: next 17 Feb 2027 · Call expires 16 Oct 2027

Pilot Hybrid Effectiveness-Implementation Trials for Mental Health Interventions

This funding opportunity supports pilot hybrid effectiveness-implementation research to optimize preventive and therapeutic mental health interventions and related implementation strategies in accessible settings such as routine care, schools, communities, or online platforms. Proposed projects must test intervention effectiveness, implementation factors, and mechanisms of action. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and foreign organizations. Clinical trials are required.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 15 Jun 2027, 15 Oct 2027 · Resubmissions: next 17 Feb 2027 · Call expires 16 Oct 2027

Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Required)

This funding opportunity supports milestone-driven feasibility and infrastructure development research followed by a well-powered clinical trial to test the effectiveness of system interventions or strategies. The aim is to improve the organization, delivery, coordination, and outcomes of mental health care. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, local and state governments, tribal governments, and non-domestic foreign organizations.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 15 Jun 2027, 15 Oct 2027 · Resubmissions: next 17 Feb 2027 · Call expires 16 Oct 2027

Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose

This funding opportunity supports preclinical and clinical research to discover and develop interventions preventing and treating substance use disorders and overdose. Funded activities include pharmacotherapies, device-based treatments, digital therapeutics, and behavioral interventions aimed at advancing candidates toward regulatory approval or clinical adoption. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, governments, and non-domestic foreign entities.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Later deadlines: 21 Jun 2027, 20 Oct 2027, 22 Feb 2028 · Resubmissions: next 22 Feb 2027 · Call expires 22 Aug 2028

BRAIN Initiative: Brain Behavior Quantification and Synchronization- Next Generation Sensor Technology Development (U01 Clinical Trial…

This funding opportunity supports the development of next-generation sensor technologies and bioelectronic devices that synchronize with brain recordings to model organismal and human behavior. It aims to foster multidisciplinary collaborations among engineers and behavioral scientists to create reliable, compact, real-time sensing tools. Eligible applicants include higher education institutions, non-profits, for-profit organizations, governments, and international foreign organizations.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s).

Resubmissions: next 15 Jun 2027

Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)

This funding opportunity supports investigator-initiated single-site clinical trials relevant to the NHLBI mission, including efficacy, comparative effectiveness, pragmatic, and implementation science trials. It utilizes a bi-phasic, milestone-driven R61/R33 mechanism to fund both the planning and execution phases. Eligible applicants include domestic and foreign organizations, though restrictions apply regarding international subawards. The multiple PD/PI model is strongly encouraged to bring together necessary expertise.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Multiple PD/PI model strongly encouraged; applicants should include expertise in biostatistics, clinical trial design, and coordination.

NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)

This notice of funding opportunity supports the implementation of investigator-initiated, milestone-driven clinical trials requiring enhanced oversight, including mechanistic studies where applicable. Funding is available for clinical trials lasting up to five years, or extended trials of six to seven years. Eligible applicants include domestic and foreign higher education institutions, nonprofits, for-profit organizations, governments, and small businesses.

Eligible countries: Any country (non-US organisations eligible)

Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)

This funding opportunity encourages multidisciplinary collaborations between life and physical sciences to apply bioengineering approaches to biomedical problems and accelerate the adoption of promising tools, methods, and techniques in basic, translational, or clinical science. It supports small teams conducting design-directed, developmental, discovery-driven, or hypothesis-driven research, including clinical trials testing functionality or validating performance. Domestic and foreign organizations are eligible to apply.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.

NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)

This funding opportunity invites investigator-initiated clinical trials addressing neurological diseases and disorders within the mission of the National Institute of Neurological Disorders and Stroke (NINDS). Supported projects include early- and middle-phase exploratory clinical trials as well as later-phase confirmatory Phase 3 or comparative effectiveness trials involving small molecules, biologics, devices, and behavioral or rehabilitation therapies across the lifespan. Various domestic and foreign organizational types are eligible to apply.

Eligible countries: Any country (non-US organisations eligible)

Who can lead: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.

DoW Parkinson's, Early Investigator Research Award

The Early Investigator Research Award supports early-career investigators in conducting innovative Parkinson's disease research. It offers two funding levels: Level 1 for fellows requiring a mentor, and Level 2 for early-career independent investigators requiring preliminary data. Eligible applicants include domestic and foreign public, private, for-profit, and nonprofit organizations. Proposed research must address specific Parkinson's disease focus areas and benefit military and civilian populations. Clinical trials are not allowed.

Eligible countries: Any country

Who can lead: Postdoctoral fellows, clinical fellows, or independent investigators within 10 years of advanced degree or residency training completion, or equivalent.

DoW Parkinson’s, Investigator-Initiated Research Award

The Investigator-Initiated Research Award supports highly rigorous, multidisciplinary, high-impact research projects addressing Parkinson's disease across basic science to clinical trials. Funded research must target at least one specific FY26 Parkinson's Research Program focus area and require preliminary data. Independent investigators at all academic levels affiliated with eligible domestic or foreign organizations can apply, with total costs capped at $2 million over a maximum three-year performance period.

Eligible countries: Any country

Who can lead: Independent investigators at all academic levels, or equivalent, affiliated with an eligible organization, regardless of ethnicity, nationality or citizenship s

Spinal Cord Injury Research Program Translational Research Award

The fiscal year 2026 Spinal Cord Injury Research Program Translational Research Award supports translational research that will accelerate the movement of promising ideas in spinal cord injury research into clinical applications. The call funds preclinical evaluations, clinical studies, and pilot trials addressing acute injury intervention, secondary health effects, psychosocial well-being, or rehabilitation. Eligible applicants include domestic and foreign, for-profit and nonprofit, public and private organizations. Proposals must name at least one spinal cord injury community partner.

Eligible countries: Any country

Who can lead: Independent investigators at all career levels can apply as Single PI. For Early-Career Partnership, at least one PI must be within 7 years of first faculty app

DoW Spinal Cord Injury, Clinical Trial Award

The fiscal year 2026 Spinal Cord Injury Research Program Clinical Trial Award supports the rapid implementation of clinical trials to significantly impact the treatment or management of spinal cord injury. Funding is available for single or partnering principal investigators, requiring at least two spinal cord community partners. Extramural and intramural organizations worldwide, including foreign and domestic, for-profit and nonprofit, are eligible to apply.

Eligible countries: Any country

Who can lead: Independent investigators at all career levels. For the partnership option, at least one PI must be an early-career investigator as specified.

DoW Spinal Cord Injury, Clinical Translation Research Award

The fiscal year 2026 Spinal Cord Injury Research Program Clinical Translation Research Award supports high-impact clinical research and clinical trials requiring preliminary studies to prepare for larger-scale implementation. The funding aims to accelerate the translation of interventions into clinical use and identify optimal diagnostic and treatment options. Eligible applicants include domestic and foreign organizations, and the call features an early-career partnership option and a requirement for community collaboration.

Eligible countries: Any country

Who can lead: Independent investigators at all career levels. For the Early-Career Partnership Option, at least one PI must be an early-career investigator.

DoW Spinal Cord Injury, Investigator-Initiated Research Award

The fiscal year 2026 Spinal Cord Injury Research Program Investigator-Initiated Research Award supports studies with the potential to contribute significantly to spinal cord injury research, patient care, and quality of life. It funds basic through translational science addressing specific programmatic goals. Eligible applicants include domestic and foreign organizations, both for-profit and non-profit. Independent investigators at all career levels may apply, with an optional early-career partnership pathway.

Eligible countries: Any country

Who can lead: Independent investigators at all career levels. For the Early-Career Partnership Option, at least one PI must be an early-career investigator.

DoW Vision, Translational Research Award

The fiscal year 2026 Vision Research Program Translational Research Award supports translational research that transforms a promising discovery into new drugs, devices, or clinical practice guidelines ready for definitive testing in clinical trials. It funds preclinical studies, clinical research, or pilot clinical trials. Independent investigators affiliated with eligible organizations worldwide can apply.

Eligible countries: Any country

Who can lead: Independent investigators affiliated with an eligible organization are eligible to be named PI on the application, regardless of ethnicity, nationality or citiz

DoW Joint Warfighter Medical, Military Medical Research and Development Award

This funding opportunity supports the logical continuation of previous Department of War-funded research and development efforts to address high-priority military medical requirements. It funds late-stage preclinical studies, technology development, translational research, and clinical trials addressing specific focus areas. Eligible applicants include domestic and foreign organizations, both for-profit and nonprofit, provided they have previously received Department of War core or Congressional Special Interest funding.

Eligible countries: Any country

Who can lead: Independent investigators affiliated with an eligible organization, regardless of ethnicity, nationality or citizenship status.

DoW Orthopaedic, Clinical Research Award

The fiscal year 2026 Orthopaedic Research Program Clinical Research Award seeks clinical research and trials evaluating orthopaedic-specific factors and interventions. It aims to generate evidence optimizing patient outcomes, informing clinical care, and benefiting Service Members, Veterans, and the general public. Projects must address specific focus areas across two research levels, supporting either clinical studies or clinical trials up to four years.

Eligible countries: Any country

Who can lead: Independent investigators at all career levels affiliated with an eligible organization, regardless of ethnicity, nationality or citizenship status.

DoW Breast Cancer, Clinical Research Extension Award

The fiscal year 2026 Breast Cancer Research Program Clinical Research Extension Award supports research that extends data collection, follow-up, and analysis of breast cancer clinical studies to increase their clinically relevant impact. It funds deeper molecular analysis, correlative studies, biomarker validation, or patient follow-up. Independent investigators affiliated with any eligible organization worldwide can apply, and the research team must include consumer advocates and meet specific programmatic challenges.

Eligible countries: Any country

Who can lead: Independent investigators affiliated with an eligible organization are eligible to be named PI, regardless of ethnicity, nationality or citizenship status.

Letter of intent (required): 4 Nov 2026

DoW Orthopaedic, Applied Research Award

The Orthopaedic Research Program Applied Research Award seeks applied research applications focused on advancing optimal treatment and restoration of function for individuals with orthopaedic injuries sustained during combat or service-related activities. The programme funds preclinical applied research projects addressing specific focus areas like battlefield infections, composite tissue regeneration, and return-to-duty strategies. Independent investigators at all career levels affiliated with eligible domestic and foreign organizations can apply.

Eligible countries: Any country

Who can lead: Independent investigators at all career levels affiliated with an eligible organization are eligible, regardless of ethnicity, nationality or citizenship status

DoW Toxic Exposures Clinical Trial Award

The Toxic Exposures Research Program Clinical Trial Award supports the advancement, execution, and analysis of clinical trials addressing symptoms, diseases, or conditions resulting from military-related toxic exposures. Funded projects range from small proof-of-concept trials to large-scale efficacy studies. Eligible applicants include extramural and intramural organizations worldwide, including foreign and domestic, for-profit and nonprofit entities.

Eligible countries: Any country

Who can lead: Independent investigators at all career levels may be named as Principal Investigator. Mentored positions are excluded.

Quantum Machine Learning

This EuroHPC JU call under Horizon Europe supports the development and validation of advanced quantum machine learning (QML) models and algorithms. The goal is to integrate quantum computing into data processing workflows to overcome computational bottlenecks, with applications in sectors including healthcare, life sciences, and image-based medical diagnosis. Research centers, universities, and technology companies can participate to strengthen European leadership in quantum computing and trustworthy AI.

Eligible countries: EU Member States and associated countries

Who can lead: Research centers, universities, industries, SMEs and technology startups, typically requiring a consortium of at least 3 independent entities from 3 EU/associat

Looking for consortium partners? Search topic HORIZON-JU-EUROHPC-2026-QML-07-01 in the EU partner search, or see “Partner search announcements” on the call page.

Valorising Horizon project results via innovation ecosystems

This call aims to bridge the structural gap between Horizon research outcomes and market-oriented support mechanisms. It funds consortia of knowledge intermediaries to scout promising innovations, launch competitive calls for third-party financial support, and provide expert mentorship, validation, and valorisation services. Applicants must be entities forming consortia acting as knowledge intermediaries within innovation ecosystems.

Eligible countries: EU Member States and associated countries

Looking for consortium partners? Search topic HORIZON-BRIDGING-2027-06-02 in the EU partner search, or see “Partner search announcements” on the call page.

Development of monoclonal antibodies to prevent and treat infections from Flaviviruses

This call aims to support the development of prophylactic and therapeutic monoclonal antibody candidates targeting specific Flaviviruses such as Dengue, Tick-borne Encephalitis, Japanese Encephalitis, West Nile Fever, Yellow Fever, and Zika. Funded activities include in-vitro and in-vivo testing, GMP batch production, and first-in-human clinical safety studies. Eligible applicants include research entities, universities, start-ups, and SMEs from EU member states and associated countries forming consortia.

Eligible countries: EU Member States and associated countries

Looking for consortium partners? Search topic HORIZON-HLTH-2027-01-DISEASE-06 in the EU partner search, or see “Partner search announcements” on the call page.

Clinical trials for advancing innovative interventions for neurodegenerative diseases

This Horizon Europe call aims to support early-stage clinical trials evaluating the safety and efficacy of innovative, multi-disciplinary therapeutic interventions combined with complementary approaches for neurodegenerative diseases. Funded projects should improve patient quality of life, utilise health data according to FAIR principles, engage relevant stakeholders including patients, and leverage research infrastructures. Eligible applicants include international consortia composed of legal entities such as universities, clinical centres, and SMEs established in EU Member States or Associated Countries.

Eligible countries: EU Member States and associated countries

Looking for consortium partners? Search topic HORIZON-HLTH-2027-02-DISEASE-14-two-stage in the EU partner search, or see “Partner search announcements” on the call page.

Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses

This topic supports the development of prophylactic and therapeutic monoclonal antibody candidates targeting specific viruses, including Ebola, Marburg, Crimean-Congo Hemorrhagic Fever, Rift Valley Fever, Enterovirus D68, or Chikungunya. Funded activities include in-vitro characterisation, in-vivo animal testing, GMP-compliant batch production, and first-in-human clinical safety trials. Proposals should advance existing candidates, with the participation of start-ups, SMEs, and entities from endemic third countries encouraged.

Eligible countries: EU Member States and associated countries

Looking for consortium partners? Search topic HORIZON-HLTH-2027-01-DISEASE-07 in the EU partner search, or see “Partner search announcements” on the call page.

Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change

This call supports research strengthening the use of the exposome approach to study global exposures and generate evidence on their health implications, focusing on integrating climate-related factors into exposome research. Funded activities include incorporating multiple climate exposures into exposomics studies, monitoring exposome changes resulting from climate pressures, advanced data analytics, and identifying exposome biomarkers. Collaborative multiscale and multidisciplinary projects involving social sciences and humanities can apply.

Eligible countries: EU Member States and associated countries

Looking for consortium partners? Search topic HORIZON-HLTH-2027-01-ENVHLTH-02 in the EU partner search, or see “Partner search announcements” on the call page.

Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications

This call supports research to reduce the incidence and severity of Adverse Drug Reactions (ADRs) resulting from multiple medications. Funded activities include leveraging pharmacogenomics, pharmacokinetics, and biomarkers for patient stratification, alongside integrating health technologies such as artificial intelligence and electronic health records into clinical practice. Proposals should also address clinical utility, guidelines, and regulatory implementation. Interdisciplinary consortia and clinical researchers, with the encouraged participation of SMEs and start-ups, can apply.

Eligible countries: EU Member States and associated countries

Looking for consortium partners? Search topic HORIZON-HLTH-2027-01-CARE-02 in the EU partner search, or see “Partner search announcements” on the call page.

Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable…

This call supports collaborative research and innovation projects aiming to develop and clinically validate multimodal predictive biomarkers for chronic non-communicable diseases, excluding cancer. Projects must leverage established artificial intelligence methodologies to integrate clinical data, candidate biomarkers, and real-world data, ensuring trustworthy AI and GDPR compliance. Eligible applicants include multidisciplinary consortia of research organizations, universities, and SMEs, with the goal of advancing personalized medicine and improving healthcare outcomes.

Eligible countries: EU Member States and associated countries

Who can lead: Entities in the EU/EFTA and/or Associated Countries leading prospective clinical studies.

Looking for consortium partners? Search topic HORIZON-HLTH-2027-02-TOOL-01-two-stage in the EU partner search, or see “Partner search announcements” on the call page.

Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential

This topic supports the development of novel or existing antiviral candidates targeting specific emerging and re-emerging viruses with epidemic potential, excluding antibodies. Funded activities include candidate discovery, structure-activity relationship optimization, in-vitro and in-vivo characterization, GMP manufacturing, and first-in-human clinical safety studies. Consortia are expected to engage with regulatory bodies, leverage research infrastructures, and encourage the participation of start-ups, SMEs, and entities from endemic third countries.

Eligible countries: EU Member States and associated countries

Looking for consortium partners? Search topic HORIZON-HLTH-2027-01-DISEASE-05 in the EU partner search, or see “Partner search announcements” on the call page.

Development of innovative antimicrobials against pathogens resistant to antimicrobials

This funding call supports the development of innovative antibacterial and antifungal agents, including antibody-based therapies, targeting specific drug-resistant pathogens to combat antimicrobial resistance. Funded activities include in-vivo testing, GMP batch production, and human clinical safety and efficacy studies. Eligible applicants include consortia of legal entities, with participation encouraged for startups and SMEs, aiming to accelerate novel candidates into human clinical trials and strengthen the EU research ecosystem.

Eligible countries: EU Member States and associated countries

Looking for consortium partners? Search topic HORIZON-HLTH-2027-01-DISEASE-08 in the EU partner search, or see “Partner search announcements” on the call page.

Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis

This call supports the development and clinical validation of multi-organ, multi-scale Virtual Human Twin models to improve prevention and diagnosis in high disease burden areas. Projects must design dynamic computational models, integrate them with healthcare workflows, and demonstrate clinical and cost-effectiveness. Consortia must be multidisciplinary and involve end-users, while contributing to the European VHT Initiative.

Eligible countries: EU Member States and associated countries

Looking for consortium partners? Search topic HORIZON-HLTH-2027-03-TOOL-04 in the EU partner search, or see “Partner search announcements” on the call page.